An interventional study of Cavilon Advanced Skin Protectant and IAD Hospital Standard Care in Incontinence-associated Dermatitis, sponsored by Solventum US LLC. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the clinical study is to assess the effects of 3M Cavilon Advanced Skin Protectant in comparison to different local IAD care regimes in hospitals (IAD: Incontinence-associated Dermatitis)
The purpose of the clinical study is to assess the effects of 3M Cavilon Advanced Skin Protectant in comparison to different local IAD care regimes in hospitals (IAD: incontinence-associated dermatitis). IAD is a skin damage caused by exposure to moisture and irritants such as urine and/or stool. The clinical appearance ranges from painful erythema to severe erosion and denudation/skin loss with or without secondary infection. The durable, long lasting skin protectant (3M study device) is formulated to attach to moist or wet skin surfaces (i.e., superficial, partial thickness skin loss) to provide better protection against moisture and irritants under challenging conditions.
Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
Device: Cavilon Advanced Skin Protectant
Marketed products are applied according to the IAD hospital standard care routine.
Device: IAD Hospital Standard Care
Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
Healing of IAD
Number and percentage of patients completely healed (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool) Note: Due to the exploratory design no formal a priori hypothesis was defined for this study. The outcome measure type for all endpoints is "other pre-specified". The effects were analyzed using descriptive statistics. No confirmatory statements can be made about the effects and no comparative statements are possible. The sponsor decided to early terminate the study after 20 evaluable patients for the intention-to-treat analysis. Reason for the early termination was the slow enrollment rate of patients and overall short length of stay in hospital.
Time frame: up to 21 days depending on length of hospitalization
Improvement of IAD Category
Number and percentage of patients improved with regard to IAD category
Time frame: Up to 21 days depending on length of hospitalization
Re-epithelialization of Skin Loss
Number and percentage of patients with 100% re-epithelialization of skin loss based on structured skin assessment (skin loss: skin is moist, as the epidermal layer is missing).
Time frame: up to 21 days depending on length of hospitalization
Time to Heal IAD
Time to complete healing of IAD in the terms of days of treatment (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool)
Time frame: Up to 21 days depending on length of hospitalization
Time to Improve in IAD Category
Time to improve in IAD category in the terms of days of treatment.
Time frame: Up to 21 days depending on length of hospitalization
Prevention of Skin Loss
Protection of IAD category 1 patients from developing IAD category 2
Time frame: up to 21 days depending on length of hospitalization
Prevention of IAD Recurrence
Protection of completely healed patients from recurrence of IAD during the study.
Time frame: up to 21 days depending on length of hospitalization
Product Cost: IAD 1A
Mean average daily product cost per patient for IAD 1A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment. Note: One patient in the group treated with Cavilon Advanced Skin Protectant stayed only one day in the study due to an unrelated Severe Adverse Event at night. This had an impact on the product cost calculation. The application interval for Cavilon Advanced Skin Protectant in this study was three days (D1, D4, D7, D10, D13, D16, D19) , while the use of IAD products for standard hospital care was based on manufacturer recommendations, which could correspond to a daily interval with multiple applications.
Time frame: up to 21 days depending on length of hospitalization
Product Cost : IAD 2A
Mean average daily cost per patient for IAD 2A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment
Time frame: up to 21 days depending on length of hospitalization
Use of Resources Involved in IAD Therapy
Additional appointments with specialists involved in IAD therapy
Time frame: Up to 21 days depending on length of hospitalization
Nursing Time Related to Cleansing
Nursing time to clean up incontinence episode
Time frame: up to 21 days depending on length of hospitalization
Nursing Time Related to Product Application
Nursing time to administer skin protectants for IAD treatment
Time frame: up to 21 days depending on length of hospitalization
Pain Related to Cleansing: IAD 1A
Pain scores related to clean up incontinence episode for IAD 1A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. For cleansing, IAD 1A patients treated with Cavilon Advanced Skin Protectant saw no change in pain due to having no pain reported at baseline nor last visit. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patients able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2, 4, 6, 8, 10), with higher score indicating more pain.
Time frame: up to 21 days depending on length of hospitalization
Pain Related to Cleansing: IAD 2A
Pain scores related to clean up incontinence episode for IAD 2A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
Time frame: up to 21 days depending on length of hospitalization
Pain Related to Product Application: IAD 1A
Pain scores related to application of skin protectants for IAD 1A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
Time frame: up to 21 days depending on length of hospitalization
Pain Related to Product Application: IAD 2A
Pain scores related to application of skin protectants for IAD 2A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
Time frame: up to 21 days depending on length of hospitalization
| Milestone | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Started | 10 | 10 |
| Iad 1a | 3 | 4 |
| Iad 2a | 7 | 6 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Number and percentage of patients completely healed (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool) Note: Due to the exploratory design no formal a priori hypothesis was defined for this study. The outcome measure type for all endpoints is "other pre-specified". The effects were analyzed using descriptive statistics. No confirmatory statements can be made about the effects and no comparative statements are possible. The sponsor decided to early terminate the study after 20 evaluable patients for the intention-to-treat analysis. Reason for the early termination was the slow enrollment rate of patients and overall short length of stay in hospital.
| Participants | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Not completely healed | 10 | 9 |
| Completely healed | 0 | 1 |
Number and percentage of patients improved with regard to IAD category
| Participants | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Worsened | 0 | 0 |
| Remained the Same | 8 | 8 |
| Improved | 2 | 2 |
Number and percentage of patients with 100% re-epithelialization of skin loss based on structured skin assessment (skin loss: skin is moist, as the epidermal layer is missing).
| Participants | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Not completely ephitelialized | 5 | 4 |
| Completely epithelialized | 2 | 2 |
Time to complete healing of IAD in the terms of days of treatment (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool)
| Days | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Time to Heal IAD | — | 13.00 |
Time to improve in IAD category in the terms of days of treatment.
| Days | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Time to Improve in IAD Category | 9.50 ± 0.707 | 5.50 ± 2.121 |
Protection of IAD category 1 patients from developing IAD category 2
| Participants | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Worsened | 0 | 0 |
| Remained the Same | 3 | 4 |
| Improved | 0 | 0 |
Protection of completely healed patients from recurrence of IAD during the study.
| IAD Recurrence Events | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Prevention of IAD Recurrence | — | 0 |
Mean average daily product cost per patient for IAD 1A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment. Note: One patient in the group treated with Cavilon Advanced Skin Protectant stayed only one day in the study due to an unrelated Severe Adverse Event at night. This had an impact on the product cost calculation. The application interval for Cavilon Advanced Skin Protectant in this study was three days (D1, D4, D7, D10, D13, D16, D19) , while the use of IAD products for standard hospital care was based on manufacturer recommendations, which could correspond to a daily interval with multiple applications.
| Euro | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Product Cost: IAD 1A | 5.56 ± 3.80 | 0.75 ± 0.06 |
Mean average daily cost per patient for IAD 2A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment
| Euro | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Product Cost : IAD 2A | 4.67 ± 2.53 | 1.21 ± 1.34 |
Additional appointments with specialists involved in IAD therapy
| Appointments | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Use of Resources Involved in IAD Therapy | 0 | 0 |
Nursing time to clean up incontinence episode
| Minutes | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Nursing Time Related to Cleansing | 13.67 ± 7.99 | 12.41 ± 8.17 |
Nursing time to administer skin protectants for IAD treatment
| Minutes | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Nursing Time Related to Product Application | 2.49 ± 3.20 | 2.02 ± 1.90 |
Pain scores related to clean up incontinence episode for IAD 1A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. For cleansing, IAD 1A patients treated with Cavilon Advanced Skin Protectant saw no change in pain due to having no pain reported at baseline nor last visit. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patients able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2, 4, 6, 8, 10), with higher score indicating more pain.
| Change in score on a scale | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Pain Related to Cleansing: IAD 1A | 0.00 ± 0.000 | -2.00 ± 3.464 |
Pain scores related to clean up incontinence episode for IAD 2A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
| Change in score on a scale | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Pain Related to Cleansing: IAD 2A | -3.00 ± 4.147 | -0.33 ± 4.274 |
Pain scores related to application of skin protectants for IAD 1A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
| Change in score on a scale | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Pain Related to Product Application: IAD 1A | 0.00 ± 0.000 | 0.00 ± 0.000 |
Pain scores related to application of skin protectants for IAD 2A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.
| Change in score on a scale | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Pain Related to Product Application: IAD 2A | -2.33 ± 4.082 | -1.20 ± 5.020 |
Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cavilon Advanced Skin Protectant | 0/10 (0%) | 1/10 (10%) | 6/10 (60%) |
| IAD Hospital Standard Care | 1/10 (10%) | 1/10 (10%) | 2/10 (20%) |
| Event | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Cardiac arrestCardiac disorders | 1/10 | 0/10 |
| Acute renal failureRenal and urinary disorders | 0/10 | 1/10 |
| Event | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care |
|---|---|---|
| Fungal infectionInfections and infestations | 2/10 | 2/10 |
| Clostridium difficile infectionInfections and infestations | 1/10 | 0/10 |
| Bacterial infectionInfections and infestations | 1/10 | 0/10 |
| Device adhesion issueProduct Issues | 1/10 | 0/10 |
| Vaginal mycosisInfections and infestations | 1/10 | 0/10 |
Patients with Incontinence-associated Dermatitis
| Age, Categorical(Participants) | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 0 | 2 |
| >=65 years | 8 | 10 | 18 |
| Sex: Female, Male(Participants) | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care | Total |
|---|---|---|---|
| Female | 8 | 5 | 13 |
| Male | 2 | 5 | 7 |
| Race and Ethnicity Not Collected(Participants) | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Cavilon Advanced Skin Protectant | IAD Hospital Standard Care | Total |
|---|---|---|---|
| Belgium | 4 | 4 | 8 |
| Germany | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Jul 2018, 7 months.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.